Skip to main content

Advertisement

ADVERTISEMENT

Type 2 Inflammation News

News
07/19/2021
“To our knowledge, this case is the first report describing rapid, successful treatment of severe atopic dermatitis and comorbid type 2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects,” researchers...
“To our knowledge, this case is the first report describing rapid, successful treatment of severe atopic dermatitis and comorbid type 2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects,” researchers...
“To our knowledge, this case is...
07/19/2021
First Report Managed Care
News
06/18/2021
“Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation,” researchers explained.
“Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation,” researchers explained.
“Dupilumab, a fully human...
06/18/2021
First Report Managed Care
News
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care

Advertisement

News
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care

Advertisement